All Content Clinical Leader

  1. Supporting Participants Through National Travel Disruptions 12/10/2025

    A sudden travel shutdown threatened a critical clinical visit. Rapid rescheduling, coordinated logistics, and clear communication ensured engagement and the ability to continue without interruption.

  2. Addressing Trial Design Hurdles Across Alzheimer’s Disease Stages 12/10/2025

    Explore how endpoint selection, rater training, and the strategic implementation of eCOA can help address the unique scientific, operational, and human considerations at each stage of AD.

  3. GxP Inventory Solution Delivers Real-Time Visibility, Operational Efficiency 12/10/2025

    Explore how unified forecasting and GxP-level inventory control can streamline your clinical supply chain, reduce risk, and strengthen oversight across every trial you run.

  4. Digital Endpoint Resource Guide: Sleep Disorders 12/10/2025

    Sensor-driven digital endpoints track sleep patterns and disruptions, standardize trial outcomes, and enable remote monitoring that reduces patient burden while improving treatment-response insights.

  5. Start Your Journey With Block Clinical 12/10/2025

    Achieve unprecedented transparency with a platform designed to help you plan, manage, and analyze patient and site support costs instantly and effortlessly.

  6. RTSM And IRT Solutions For Clinical Trials 12/10/2025

    Global leader in RTSM/IRT, helping sponsors and CROs speed study start-up, optimize supply, and manage complex trials with confidence.

  7. The Site Perspective: Why Ambient AI Is The Missing Link In Clinical Trial Data Integrity 12/10/2025

    Discover how AI ambient listening has changed the way Mikel Daniels, DPM, MBA, and his team conduct clinical research at WeTreatFeet Podiatry. 

  8. Why HEOR Keeps Arriving Too Late — And How ClinOps Can Fix It 12/9/2025

    Rob Abbott, CEO of ISPOR, breaks down why HEOR timing keeps clashing with ClinOps timelines and offers practical ways to integrate value, evidence, and payer expectations much earlier in development.

  9. Takeda Keeps Patients The Focus Of PDTs For Rare Disease 12/9/2025

    Takeda’s Kristina Allikmets, MD, Ph.D, shares how her team incorporates patient voices and prioritizes innovations to reduce treatment burden, expand access, and develop plasma-derived therapies for rare diseases.

  10. Overcoming Cell Therapy Design Challenges To Treat AML And Other Life-Threatening Diseases 12/9/2025

    CERo CEO Chris Ehrlich discusses how a focus on safety, robust manufacturing, and key early indicators is rewriting the playbook for future personalized medicine trials.